Genprex, Inc. has announced that research conducted under its collaboration with Meharry Medical College will be featured at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting. This event is scheduled for November 4-7, 2026, in National Harbor, Maryland. The research focuses on the role of TUSC2, a tumor suppressor gene utilized in Genprex's lead oncology candidate, REQORSA (quaratusugene ozeplasmid), in mitochondrial biology and aging processes.

The significance of this presentation lies in its potential implications for both Genprex and the broader pharmaceutical industry. By exploring the biological activities of TUSC2 and REQORSA, Genprex aims to expand its understanding of these elements and their relevance to therapeutic applications beyond oncology. This could set the stage for new developments in the pharmaceutical preparations sector, particularly in addressing aging-related conditions.

Background on Genprex, Inc.

Genprex, Inc. operates in the pharmaceutical preparations industry, specifically focusing on innovative therapies for cancer and diabetes. The company is publicly traded on the Nasdaq under the ticker symbol GNPX. Established in Texas, Genprex has been actively involved in research collaborations to enhance its product development and clinical trials.

What the Filing Says

According to the recent SEC filing, Genprex stated, "On October 28, 2026, Genprex, Inc. issued a press release announcing that research conducted under its sponsored research collaboration with Meharry Medical College will be featured at the GSA 2026 Annual Scientific Meeting." The research investigates TUSC2's role in mitochondrial biology and aging, contributing to the understanding of REQORSA's biological mechanisms.

Impact

This development may affect various stakeholders, including researchers, healthcare professionals, and investors in the pharmaceutical preparations industry. The findings presented at the GSA meeting could influence future research directions and therapeutic strategies, particularly in the context of aging-related diseases.

What's Next

Following the presentation at the GSA Annual Scientific Meeting, Genprex may continue to expand its research collaboration with Meharry Medical College. However, the filing does not specify any immediate next steps beyond the conference.